While the use of pharmacological doses of recombinant human Growth Hormone is known to lead to hyperglycemia, insulin resistance, fluid retention, and carpal tunnel syndrome [42], the utilization of analogs of growth hormone-releasing factor (GRF)/growth hormone-releasing hormone (GHRH) presents an alternative approach. The gene discussed is GH1; the disease is Hyperglycemia.